Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma

Trial Profile

Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Everolimus (Primary) ; Hydroxychloroquine (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Dec 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
    • 07 Dec 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top